Historical geographies of the future: airships and the making of imperial atmospheres

This article explores the elemental encounters and imaginative geographies of empire to develop a new means of engaging with the historical geographies of the future. Futures have recently become an important topic of historical and cultural inquiry, and historical geographers have an important role to play in understanding the place of the future in the past and in interrogating the role of posited futures in shaping action in historical presents. Drawing on literature from science and technology studies, a framework is developed for engaging with the material and imaginative geographies that coalesce around practices of imagination, expectation, and prediction. This framework is then used to reconstruct efforts to develop airship travel in the British Empire in the 1920s and 1930s. At a moment of imperial anxiety, airships were hoped to tie the empire together by conveying bodies, capital, and military capacity between its furthest points. Confident projections of the colonization of global airspace were nonetheless undermined by material encounters with a vibrant, often unpredictable atmospheric environment. The article aims to spur renewed work on the historical geographies of the future, while also contributing to debates on the cultural and political geographies of the atmosphere and of atmospheric knowledge making. Key Words: atmosphere, empire, future, mobility, technology

Bicycle-sharing systems in an alternative/diverse economy perspective: a sympathetic critique

This contribution puts bicycle-sharing systems (BSSs) as a rather recent, environmentally friendly form of urban mobility in the context of broader societal changes. More specifically, we discuss to what extent BSS and their various modes of organisation can be regarded as an “alternative” consumption practice, explicitly designed to deliver more social just outcomes, taking the diverse economy framework of Gibson-Graham as a key tool of analysis. Our examination unfolds a range of limitations of BSSs for (strong) sustainable development, but also a number of obvious and less obvious prospects and opportunities

Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl.

HX575 was approved in the European Union in August 2007 as the first-ever biosimilar epoetin-α product. The present study extended the safety database on HX575 by monitoring adverse events (AEs) in clinical practice. Hemoglobin (Hb) levels and HX575 doses were recorded for the assessment of efficacy. This open, 6-month single-arm study was conducted in 10 European countries with a target enrollment of 1,500 patients with anemia due to chronic kidney disease (CKD). HX575 was intravenously (i.v.) administered aiming at an Hb target of 10 - 12 g/dl. Most patients (92.3%) had already received erythropoiesis stimulating agents (ESAs) treatment before enrolment into this study; the recorded treatments mainly comprised i.v. or subcutaneous (s.c.) administration of epoetin-α, epoetin-β or darbepoetin. The study period covered 770 patient years. The observed AE profile was in line with expectations for this patient population. Thrombotic vascular events (TVEs) were reported in 11.9% of patients (0.2612 per patient year). Tumor incidence was 1.4% (0.0299 per patient year). No subject developed anti-epoetin antibodies. Mean Hb levels were effectively maintained between 11.2 and 11.3 g/dl following the conversion from a broad spectrum of pre-study ESA treatments with stable overall mean i.v. HX575 doses. The proportion of patients within the Hb target range increased from 57.5% at baseline to 66.8% at study end

Prospective multicenter study of HX575 (biosimilar epoetin-\u3b1) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl

HX575 was approved in the European Union in August 2007 as the first-ever biosimilar epoetin-\u3b1 product. The present study extended the safety database on HX575 by monitoring adverse events (AEs) in clinical practice. Hemoglobin (Hb) levels and HX575 doses were recorded for the assessment of efficacy. This open, 6-month single-arm study was conducted in 10 European countries with a target enrollment of 1,500 patients with anemia due to chronic kidney disease (CKD). HX575 was intravenously (i.v.) administered aiming at an Hb target of 10 - 12 g/dl. Most patients (92.3%) had already received erythropoiesis stimulating agents (ESAs) treatment before enrolment into this study; the recorded treatments mainly comprised i.v. or subcutaneous (s.c.) administration of epoetin-\u3b1, epoetin-\u3b2 or darbepoetin. The study period covered 770 patient years. The observed AE profile was in line with expectations for this patient population. Thrombotic vascular events (TVEs) were reported in 11.9% of patients (0.2612 per patient year). Tumor incidence was 1.4% (0.0299 per patient year). No subject developed anti-epoetin antibodies. Mean Hb levels were effectively maintained between 11.2 and 11.3 g/dl following the conversion from a broad spectrum of pre-study ESA treatments with stable overall mean i.v. HX575 doses. The proportion of patients within the Hb target range increased from 57.5% at baseline to 66.8% at study end